Patient Registry of Intrathecal Ziconotide Management (PRIZM): An Open-Label, Long Term, Multi-Center, Observational Study of Ziconotide (Prialt) Solution, Intrathecal Infusion, in Patients With Severe Chronic Pain
Phase of Trial: Phase IV
Latest Information Update: 20 Mar 2017
Price : $35 *
At a glance
- Drugs Ziconotide (Primary)
- Indications Pain
- Focus Therapeutic Use
- Acronyms PRIZM
- Sponsors Jazz Pharmaceuticals Inc
- 14 Mar 2017 Status changed from active, no longer recruiting to completed.
- 11 May 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016.
- 11 May 2016 Status changed from recruiting to active, no longer recruiting.